Effects of GLP-1 Receptor Agonists on Muscle Mass, Strength, and Quality in MASLD: A Systematic Review
Weight-loss medications used by millions don't appear to cause concerning muscle loss in people with fatty liver disease, addressing a major safety worry.
This systematic review of 12 studies (n=810) found that GLP-1 receptor agonists do not cause clinically meaningful sarcopenia in MASLD patients—a critical safety concern given widespread GLP-1 use in metabolically compromised patients. Evidence is limited by heterogeneous methods, but the reassuring muscle-preservation signal is clinically actionable.
What the study was
- Study design
- Systematic review (n=12 studies, total n=810 participants across MEDLINE/PubMed, Embase, Cochrane through Dec 2025)
- Population
- Adults with metabolic dysfunction-associated steatotic liver disease (MASLD) on GLP-1 receptor agonists
- Sample size
- 810
- Category
- Drug Development
- Maturity
- Validated
- Journal
- Liver International
Why it surfaced
Systematic review from two major academic centers addressing a critical clinical uncertainty for one of the most prescribed drug classes; findings directly inform clinical guidance on GLP-1 prescribing in liver disease.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.